MED-LATANOPROST SOLUTION

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Bahan aktif:

LATANOPROST

Tersedia dari:

GENERIC MEDICAL PARTNERS INC

Kode ATC:

S01EE01

INN (Nama Internasional):

LATANOPROST

Dosis:

50MCG

Bentuk farmasi:

SOLUTION

Komposisi:

LATANOPROST 50MCG

Rute administrasi :

OPHTHALMIC

Unit dalam paket:

2.5ML/5ML

Jenis Resep:

Prescription

Area terapi:

PROSTAGLANDIN ANALOGS

Ringkasan produk:

Active ingredient group (AIG) number: 0132916002; AHFS:

Status otorisasi:

APPROVED

Tanggal Otorisasi:

2014-07-30

Karakteristik produk

_Page 1 of 28_
_MED-LATANOPROST (Latanoprost)_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MED-LATANOPROST
Latanoprost ophthalmic
solution
Solution, 50 mcg/mL, Ophthalmic
Prostaglandin F
2α
analogue
Generic Medical Partners Inc.
251 Consumers Road Suite 1200
Toronto, Ontario
M2J 4R3
Date of Initial Authorization:
June 25, 2014
Date of Revision:
July 27, 2023
Submission Control Number: 273339
_Page 2 of 28_
_MED-LATANOPROST (Latanoprost)_
_ _
RECENT MAJOR LABEL CHANGES
None at the time of most recent authorization
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
4
4.1
Dosing Considerations
...............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
......................................................... 4
4.4
Administration
..........................................................................................................
5
4.5
Missed Dose
........................................